BACKGROUND AND PURPOSE: Babies are frequently exposed to hypoxia and ischemia during the perinatal period as a result of stroke or problems with delivery or respiratory management post delivery. The only U.S. Food and Drug Administration-approved treatment for acute stroke is the administration of tPA. Nonetheless, basic science studies indicate that tPA exhibits both beneficial and deleterious effects on central nervous system function. Cerebral hypoxia/ischemia (H/I) impairs dilation to hypercapnia and hypotension in the newborn pig. We investigated the role of exogenous and endogenous plasminogen activators (PA) in piglet hypercapnic and hypotensive dilator impairment after H/I. METHODS: Responses to dilator stimuli were measured in chloralose-anesthetized piglets equipped with a closed cranial window before and after hypoxia (Po2 35 mm Hg) and subsequent global cerebral ischemia. Data (n=6) were analyzed by repeated-measures analysis of variance. RESULTS: Hypercapnic (Pco2 75 mm Hg) and hypotensive (mean arterial blood pressure decreased by 45%) pial artery dilation (PAD) was blunted after H/I and reversed to vasoconstriction in animals pretreated with tPA or uPA (10(-7) mol/L; 26+/-2, 11+/-1, and -4+/-1% for hypercapnia before, after H/I, and after H/I with tPA). In animals pretreated with EEIIMD (10(-7) mol/L), a peptide that binds uPA and tPA but does not affect proteolysis or soluble uPA receptor (suPAR, 10(-7) mol/L), which binds but does not affect the proteolytic activity of uPA. PAD induced by hypercapnia and hypotension was attenuated to a lesser extent (25+/-2 and 17+/-1% for hypercapnic PAD before and after H/I in EEIIMD-pretreated animals and 21+/-1 and 18+/-2% in suPAR-pretreated animals). CONCLUSIONS: These data show that exogenous PA administration potentiates the impairment of hypercapnic and hypotensive PAD that occurs after H/I. Inhibition of endogenous PA may ameliorate the impairment of PAD induced by hypercapnia and hypotension PAD that develops after hypoxic central nervous system injury of diverse etiologies.
BACKGROUND AND PURPOSE: Babies are frequently exposed to hypoxia and ischemia during the perinatal period as a result of stroke or problems with delivery or respiratory management post delivery. The only U.S. Food and Drug Administration-approved treatment for acute stroke is the administration of tPA. Nonetheless, basic science studies indicate that tPA exhibits both beneficial and deleterious effects on central nervous system function. Cerebral hypoxia/ischemia (H/I) impairs dilation to hypercapnia and hypotension in the newborn pig. We investigated the role of exogenous and endogenous plasminogen activators (PA) in piglet hypercapnic and hypotensive dilator impairment after H/I. METHODS: Responses to dilator stimuli were measured in chloralose-anesthetized piglets equipped with a closed cranial window before and after hypoxia (Po2 35 mm Hg) and subsequent global cerebral ischemia. Data (n=6) were analyzed by repeated-measures analysis of variance. RESULTS: Hypercapnic (Pco2 75 mm Hg) and hypotensive (mean arterial blood pressure decreased by 45%) pial artery dilation (PAD) was blunted after H/I and reversed to vasoconstriction in animals pretreated with tPA or uPA (10(-7) mol/L; 26+/-2, 11+/-1, and -4+/-1% for hypercapnia before, after H/I, and after H/I with tPA). In animals pretreated with EEIIMD (10(-7) mol/L), a peptide that binds uPA and tPA but does not affect proteolysis or soluble uPA receptor (suPAR, 10(-7) mol/L), which binds but does not affect the proteolytic activity of uPA. PAD induced by hypercapnia and hypotension was attenuated to a lesser extent (25+/-2 and 17+/-1% for hypercapnic PAD before and after H/I in EEIIMD-pretreated animals and 21+/-1 and 18+/-2% in suPAR-pretreated animals). CONCLUSIONS: These data show that exogenous PA administration potentiates the impairment of hypercapnic and hypotensive PAD that occurs after H/I. Inhibition of endogenous PA may ameliorate the impairment of PAD induced by hypercapnia and hypotension PAD that develops after hypoxic central nervous system injury of diverse etiologies.
Authors: William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi Journal: Am J Physiol Regul Integr Comp Physiol Date: 2010-06-10 Impact factor: 3.619
Authors: William M Armstead; Kumkum Ganguly; John Riley; J Willis Kiessling; Douglas B Cines; Abd A R Higazi; Sergei Zaitsev; Vladimir R Muzykantov Journal: Pediatr Crit Care Med Date: 2011-11 Impact factor: 3.624
Authors: William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi Journal: Am J Physiol Heart Circ Physiol Date: 2010-04-30 Impact factor: 4.733
Authors: Taher Nassar; Serge Yarovoi; Rami Abu Fanne; Otailah Waked; Timothy C Allen; Steven Idell; Douglas B Cines; Abd Al-Roof Higazi Journal: Am J Respir Cell Mol Biol Date: 2011-05-26 Impact factor: 6.914
Authors: A A Higazi; M El-Haj; A Melhem; A Horani; O Pappo; C E Alvarez; N Muhanna; S L Friedman; R Safadi Journal: Clin Exp Immunol Date: 2008-02-14 Impact factor: 4.330